Projecten per jaar
Vingerafdruk
Verdiep u in de onderzoeksgebieden waarop Sylvia Faict actief is. Deze onderwerplabels komen uit het werk van deze persoon. Samen vormen ze een unieke vingerafdruk.
- 1 Soortgelijke profielen
Samenwerkingen en hoofdonderzoeksgebieden uit de afgelopen vijf jaar
Recente externe samenwerking op landen-/regioniveau. Duik in de details door op de stippen te klikken of
-
FWOTM1301: 'MICRO-MM’: Bacteriële extracellulaire vesikels als diagnostische merker en therapeutisch instrument in de behandeling van Multipel Myeloom
Faict, S. (Administrative Promotor)
1/10/25 → 30/09/30
Project: Fundamenteel
-
FWOTM771: Exosomale communicatie bij Multipel Myeloom: vriend of vijand?
Vanderkerken, K. (Administrative Promotor) & Faict, S. (Mandataris)
1/10/15 → 30/09/19
Project: Fundamenteel
-
Adrenergic stimulation of bone marrow immunity differentially affects myeloma growth and immunotherapy responses
Satilmis, H., Verheye, E., Faict, S., Heestermans, R., De Becker, A., Vanderkerken, K., De Bruyne, E., Menu, E., Sloan, E. K. & De Veirman, K., 28 okt. 2026, In: Cancer Letters. 659, 12 blz., 218802.Onderzoeksoutput: Article › peer review
-
IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma
Satilmis, H., Denis, A., Verheye, E., Van der Vreken, A., Zhan, D., Calliauw, E., Törngren, M., Eriksson, H., Faict, S., De Bruyne, E., Menu, E., Vanderkerken, K. & De Veirman, K., 4 mei 2026, In: Journal of Experimental & Clinical Cancer Research. 45, 18 blz., 172.Onderzoeksoutput: Article › peer review
Open Access -
The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism
Tu, C., Van der Vreken, A., Faict, S., Ates, G., Massie, A., De Veirman, K., De Bruyne, E., Vanderkerken, K. & Menu, E., 1 mrt. 2026, In: Cancer Letters. 640, 15 blz., 218245.Onderzoeksoutput: Article › peer review
1 Citaat (Scopus) -
Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in Relapsed/Refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study
Ho, P. J., Quach, H., Delimpasi, S., Santoro, A., Lee, C. H.-S., Kint, N., Faict, S., Yu, Y., Catalani, O., Mishra, A., Tyagi, T., Devlin, C., Sheikh, S. & Dimopoulos, M., 3 nov. 2025, In: Blood. 146, blz. 700-701 2 blz.Onderzoeksoutput: Meeting abstract (Journal)
-
Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments
Planken, S., Faict, S., Trullemans, F., Linskens, E., Vandepoele, K. & De Becker, A., aug. 2024, In: Cureus. 16, 8, blz. 1-5 5 blz., e66291.Onderzoeksoutput: Article › peer review
Open AccessBestand22 Downloads (Pure)
Prijzen
-
Best oral presentation - oncology research center day
Faict, S. (Recipient), 19 okt. 2018
Prijs: Prize (including medals and awards)
-
Early Career Scientist Scholarship
Faict, S. (Recipient), mrt. 2019
Prijs: Prize (including medals and awards)
-
New Investigator Award Cancer and Bone Society 2018 meeting
Faict, S. (Recipient), 2018
Prijs: National/international honour
-
IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of Multiple Myeloma
Satilmis, H. (Speaker), Denis, A. (Contributor), Verheye, E. (Contributor), Van der Vreken, A. (Contributor), Zhan, D. (Contributor), Calliauw, E. (Contributor), Törngren, M. (Contributor), Eriksson, H. (Contributor), Faict, S. (Contributor), De Bruyne, E. (Contributor), Menu, E. (Contributor), Vanderkerken, K. (Contributor) & De Veirman, K. (Contributor)
6 feb. 2026Activiteit: Talk or presentation at a conference
-
EHA Congres
De Becker, A. (Participant), Faict, S. (Participant) & Staessens, S. (Participant)
12 jun. 2025 → 15 jun. 2025Activiteit: Participation in conference
-
EHA
De Becker, A. (Participant) & Faict, S. (Participant)
8 jun. 2023 → 11 jun. 2023Activiteit: Participation in conference
-
Inhibition of multiple myeloma exosomes prevents bone loss and reduces tumor growth
Faict, S. (Speaker)
1 jul. 2018Activiteit: Talk or presentation at a conference
-
Inhibition of multiple myeloma exosomes prevents bone loss and reduces tumor growth.
Menu, E. (Speaker) & Faict, S. (Speaker)
2018Activiteit: Talk or presentation at a conference
Scriptie
-
Exosomal Communication in Multiple Myeloma-Friend or Foe-
Faict, S. ((PhD) Student), Menu, E. (Promotor), Vanderkerken, K. (Promotor), Schots, R. (Promotor), Jernberg-Wiklund, H. (Jury), De Wever, O. (Jury), van Grunsven, L. A. (Jury), Rooman, I. (Jury) & Breckpot, K. (Jury), Menu, E. (Promotor), Vanderkerken, K. (Promotor), Schots, R. (Promotor), Jerneberg-Wiklund, H. (Jury), De Wever, O. (Jury), van Grunsven, L. (Jury), Rooman, I. (Jury) & Breckpot, K. (Jury), 23 sep. 2019Scriptie/Masterproef: Doctoral Thesis